6 курс / Кардиология / Некоронарогенные_болезни_сердца_Коваленко_В_Н_,_Несукай_Е_Г_

1663 ,

) -

12,5-25 .

, ,

27%, -

— 36%, — 22%. -

31%,

35%, — 29%. -

(75-100 -) -

.

, , -

. -

-

.

-

-1- -

( II)

-

. , -

II -

-

,

.

CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study, 1987), -

-

27%. -

SOLVD (Studies of Left Ventricular

360

Dysfunction, 1990-1991 .), SAVE (Survival and Ventricular Enlargement, 1992 .), V-HeFT II (Vasodilator Heart Failure Trial, 1991)

-

. 30 -

,

7000 , -

23%

35%.

-

,

-

,

,

, -

, -

.

:

),

•« » (

),

•(

) , , , ,

,

•,

•.

:

•II,

•,

•, -

-1,

,

(1-7),

2,

•,

•, .

-

. -

, -

. -

:

-

N0 . , -

, N0 -

.

(

, 1999) -

:

•,

,

. (

) , ,

.

,

;

•, , , ,

, ,

; -

,

; , -

,

;

.

(«

» ), , ,

,

;

•,

, ,

,

» ,

.

-

( -

< 80 . .),

(> 3 ), -

,

(> 5,5 ).

-

, 3-7

( — 20 — 150 ).

, -

, -

, , , -

.

, -

.

II — -

,

. -

,

II .

1988 . 90- -

: -

, , , .

ELITE (Evaluation of Losartan in the Elderly, 1997)

II -

— -

.

ELITE II (1999).

RESOLVD (Randomised Evaluation of Strategy for Lert Ventricular Dysfunction, 1997, 1999) , -

( , -

) -

-

.

-

II -

. -

,

-11 -

.

-

II -

:

•,

II

,

,

, ,

,

II;

364

(

). II, -

, , ,

, .

-

, -

.

,

AV- , -

. ,

-

:

, ( , -

),

,

—

.

« » -

, -

,

.

, -, , ,

.

, -

:

•,

•, ,

•,

•—

,

•,

•,

•,

•,

•.

.

,

. -

.

-

DIG (Digitalis Investigation Group, 1997), -

7788 -

, 0,125-0,5 , -

,

), -

, -

, -

. -

.

-

,

-

. ,

-

,

-

, -

,

(PROVED, 1993)

(RADIANCE, 1993).

-

-

. ,

-

( ) -

,

, ( -

)

.

.

J. . Petrie (1997)

:

1),

;

(IIIIV ):

)

,) 1

,)

( 25%) -

( 0,55

).

, -

-

, -, ,

-a pe ope opo .

-

.

-

, ,

-

-

.

8090- -

,

IIIIV

, -

( )DA- ( ),

( , ) -

( , , ). -

-

, -

, .

Xamoterol in Severe Heart Failure Study (1990) -

IIIIV , -

.

, ( , ,

) , -

- -

. -

PROMISE (Prospective Randomized Milrinone Survival Evaluation, 1991), 1088

IIIIV -

0,35, 6 -

28%, -

— 34%, — 69%,

-

. .

PICO (Pimobendan In Congestive heart failure) , -

, ,

.

, 1,8

, . -

19% , -

, 9% .

-

, -

-

, 2

— VesSG (Vesnarinon Study Group) VEST (Vesnarinone Evaluation of Survival Trial).

-

, ,

.

, -

- . ,

-

— REFLECT (Randomized Evaluation of Flosequinan on Exercise Tolerance, 1993), FACET (Flose- quinan-Angiotensin Converting Enzyme inhibitor Trial, 1993), PROFILE (Prospective Randomized Flosequinan Longevity Evaluation). -

, , .

PRIME-II (Second Prospective Randomized study of Ibopamine on Mortality and Efficacy) -

DA1,- D 2 -

-

. -

, .

-

4 -

, :

, , , . -

,

. -

, -

. -

,

-

. , -

2530%, -

.

, -

. -

-

. -

, -

, -

-

.

, -

-

.

-

-, -

. , -

, -

.

( , , -

) , -

, -

.

( , ) -

, ,

, .

-

-

V-HeFT I (Vasodilator Heart Failure Trial, 1986) 642 -

. (20 ),

(300 ) (160 )

, 2,3 . -

, -

( 38%).

, -

. , -

.

-

— — -

,

, -

, .

-

.

-

, -

. -

, -

-

. -

, -

( , ).

-

V-HeFT III (1996) 18

451 .

5 2 . -

-

, ( -

).

PRAISE (1996) 1153 -

< 30%.

5-10 13,8 . -

,

-

46%, -

. PRAISE II (2000), 1652 -

IIIIV

21 %,

, -

. ,

,

.

, -

-

.

-a pe ope opo . -

,

, -

-

.

-

.

-a pe ope opo 10 000 -

35-45%,

20 -

. ,

. ,

, -

-

.

,

. -

, . -

, -

.

(MDC — Metoprolol in Idiopathic Dilated Cardiomyopathy, 1993)

(CIBIS — Cardiac Insufficiency Bisoprolol Study, 1994), -

, -

-

.

MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Heart Failure, 1999)

3991 -

35% -

, .

CIBISII (1994), -

2647 16 , ,

1,25-10 , , -

34%, -

20 %,

47%. -

, , -

, -

, .

:

•: , -

, , ;

•— -

,

;

•;

•;

, ;

•, ;

•—

-

;

•-

;

•—

.

, -

-

,

.

-

, -

, -

( ) ,- , , -

.

-atf-

-

, -

; , -

, .

, , -

,

, -

.

-, ,

800 , -

, ,

, .

PRECISE (Prospective Randomized Evaluation of Carvediolon Symptoms and Exercise, 1996) -

278

39%

46% — -

.

MOCHA (Multicenter Oral Carvediol Heart Failure Assessment, 1996)

345 -

73% -

45%.

-

4 ,

65% .

:

•( -

,

, );

;

•;

•;

•;

•;

•;

•;

•.

COPERNICUS (Carvedilol Prospective Randomized

Cumulative Survival Trial, 2000) 2000

25%

. -

-

.

.

, -

-

, COMET (Carvedilol or Metoprolol European Trial), -

3000

4 .

2001 .

-

-a pe ope opo , -

. -

-

.

, ,

, :

1),

;

2)2- 3

;

.

.

, , -

, , -

.

, -

-

, . -

( , , , -) .

— 5 , 1,25 , 3,125 .

-

. -

, -

, . -

.

-

, -

, .

-

. 1|8 ,

2- 3 .

6- 12 -

. -

, -

( . 15).

-a pe ope opo -

1020% , -

, ,

15.

, -

— .

.

3-4 -

. -

-

, , .

-

( -

, ) — ,

. -

,

,

, II

, -. III ( -

IMPRESS, OVERTURE),

.

-

.

, -

50%, 1,3-1,5 . -

-

,

.

, -

, -

, . -

, -

,

( )

. , -

-, ,

-

. -

, -

.

-

.

, 10 -

« -

» « » , -

:

•,

«

»,

, ;

•,

,

, ,

;

,

, ,

,

, ;

•,

« »

,

.

-

:

;

•;